Citations

Showing 10 of 108083 citations.

Targeting senescent cholangiocytes and activated fibroblasts with B‐cell lymphoma‐extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2−/− ) mice
Moncsek, Anja , Alsuraih, Mohammed, Trussoni, Christy E. , O’Hara, Steven P. , Splinter, Patrick L., Zuber, Camille, Patsenker, Eleonora , Valli, Piero V., Fingas, Christian D., Zhu, Yi , Tchkonia, Tamar , Kirkland, James L. , Müllhaupt, Beat , Mertens, Joachim C. , Al-Suraih, Mohammed S, Tchkonia, T , Weber, Achim , Gores, Gregory J. , LaRusso, Nicholas F. , Zhu, Yi

Mayo Clinic

Hepatology | August 12, 2017 | Volume: 67 | Issue: 1 | Pages: 247-259

10.1002/hep.29464 | PMID 28802066 Get It

Cholangiocyte senescence has been linked to primary sclerosing cholangitis (PSC). Persistent secretion of growth factors by senescent cholangiocytes leads to the activation of stromal fibroblasts (ASFs), which are drivers of fibrosis. The activated phenotype of ASFs is characterized by an increased sensitivity to apoptotic stimuli. Here, we examined the mechanisms of apoptotic priming in ASFs and explored a combined targeting strategy to deplete senescent cholangiocytes and ASFs from fibrotic tissue to ameliorate liver fibrosis. Using a coculture system, we determined that senescent cholangiocytes promoted quiescent mesenchymal cell activation in a platelet‐derived growth factor (PDGF)‐dependent manner. We also identified B‐cell lymphoma‐extra large (Bcl‐xL) as a key survival factor in PDGF‐activated human and mouse fibroblasts. Bcl‐xL was also up‐regulated in senescent cholangiocytes. In vitro , inhibition of Bcl‐xL by the small molecule Bcl‐2 homology domain 3 mimetic, A‐1331852, or Bcl‐xL‐specific small interfering RNA induced apoptosis in PDGF‐activated fibroblasts, but not in quiescent fibroblasts. Likewise, inhibition of Bcl‐xL reduced the survival and increased apoptosis of senescent cholangiocytes, compared to nonsenescent cells. Treatment of multidrug resistance 2 gene knockout ( Mdr2−/− ) mice with A‐1331852 resulted in an 80% decrease in senescent cholangiocytes, a reduction of fibrosis‐inducing growth factors and cytokines, decrease of α‐smooth muscle actin–positive ASFs, and finally in a significant reduction of liver fibrosis. Conclusion: Bcl‐xL is a key survival factor in ASFs as well as in senescent cholangiocytes. Treatment with the Bcl‐xL‐specific inhibitor, A‐1331852, reduces liver fibrosis, possibly by a dual effect on activated fibroblasts and senescent cholangiocytes. This mechanism represents an attractive therapeutic strategy in biliary fibrosis. (H epatology 2018;67:247‐259).
Impact statement: “Integration of multiple health information systems for quality improvement of radiologic care”
Tollefson, Chris

Mayo Clinic

IISE Transactions on Healthcare Systems Engineering | August 12, 2017 | Volume: 7 | Issue: 3 | Pages: 168-168

10.1080/24725579.2017.1357396 Get It

Assessment of advanced hepatic MR elastography methods for susceptibility artifact suppression in clinical patients
Wang, Jin , Glaser, Kevin J. , Zhang, Tianhui , Shan, Qungang , He, Bingjun , Yin, Meng , Dzyubak, Bogdan , Kugel, Jennifer L., Kruse, Scott A., Grimm, Roger C., Venkatesh, Sudhakar K. , Dzyubak, Bogdan , Venkatesh, Sudhakar K , Yin, Meng , Chen, Jun , Ehman, Richard L.

Mayo Clinic

Journal of Magnetic Resonance Imaging | August 12, 2017 | Volume: 47 | Issue: 4 | Pages: 976-987

10.1002/jmri.25818 | PMID 28801939 Get It

PurposeTo assess the success rate, image quality, and the ability to stage liver fibrosis of a standard 2D gradient‐recalled echo (GRE) and four different spin‐echo (SE) magnetic resonance elastography (MRE) sequences in patients with different liver iron concentrations.Materials and MethodsA total of 332 patients who underwent 3T MRE examinations that included liver fat and iron quantification were enrolled, including 136 patients with all five MRE techniques. Thirty‐four patients had biopsy results for fibrosis staging. The liver stiffness, region of interest area, image quality, and success rate of the five sequences were compared in 115/136 patients. The area under the receiver operating characteristic curves (AUCs) and the accuracies for diagnosing early‐stage fibrosis and advanced fibrosis were compared. The effect of BMI (body mass index), the R2* relaxation time, and fat fraction on the image quality and liver stiffness measurements were analyzed.ResultsThe success rates were significantly higher in the four SE sequences (99.1–100%) compared with GRE MRE (85.3%) (all P < 0.001). There were significant differences of the mean ROI area between every pair of sequences (all P < 0.0001). There were no significant differences in the AUC of the five MRE sequences for discriminating advanced fibrosis (10 P‐values ranging from 0.2410–0.9171). R2* had a significant effect on the success rate and image quality for the noniron 2D echo‐planar imaging (EPI), 3D EPI and 2D GRE (all P < 0.001) sequences. BMI had a significant effect on the iron 2D EPI (P = 0.0230) and iron 2D SE (P = 0.0040) sequences.ConclusionAll five techniques showed good diagnostic performance in staging liver fibrosis. The SE MRE sequences had higher success rates and better image quality than GRE MRE in 3T clinical hepatic imaging.Level of Evidence: 3Technical Efficacy: Stage 5J. Magn. Reson. Imaging 2018;47:976–987.
The Sound Quality of Cochlear Implants: Studies With Single-sided Deaf Patients
Dorman, Michael F. , Natale, Sarah Cook, Butts, Austin McRae, Zeitler, Daniel M. , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | August 12, 2017 | Volume: 38 | Issue: 8 | Pages: e268-e273

10.1097/mao.0000000000001449 | PMID 28806337 Get It

Objective: The goal of the present study was to assess the sound quality of a cochlear implant for single-sided deaf (SSD) patients fit with a cochlear implant (CI). Background: One of the fundamental, unanswered questions in CI research is “what does an implant sound like?” Conventional CI patients must use the memory of a clean signal, often decades old, to judge the sound quality of their CIs. In contrast, SSD-CI patients can rate the similarity of a clean signal presented to the CI ear and candidate, CI-like signals presented to the ear with normal hearing. Methods: For Experiment 1 four types of stimuli were created for presentation to the normal hearing ear: noise vocoded signals, sine vocoded signals, frequency shifted, sine vocoded signals and band-pass filtered, natural speech signals. Listeners rated the similarity of these signals to unmodified signals sent to the CI on a scale of 0 to 10 with 10 being a complete match to the CI signal. For Experiment 2 multitrack signal mixing was used to create natural speech signals that varied along multiple dimensions. Results: In Experiment 1 for eight adult SSD-CI listeners, the best median similarity rating to the sound of the CI for noise vocoded signals was 1.9; for sine vocoded signals 2.9; for frequency upshifted signals, 1.9; and for band pass filtered signals, 5.5. In Experiment 2 for three young listeners, combinations of band pass filtering and spectral smearing lead to ratings of 10. Conclusion: The sound quality of noise and sine vocoders does not generally correspond to the sound quality of cochlear implants fit to SSD patients. Our preliminary conclusion is that natural speech signals that have been muffled to one degree or another by band pass filtering and/or spectral smearing provide a close, but incomplete, match to CI sound quality for some patients.
Computational Fluid Dynamics of a Fatal Ruptured Anterior Communicating Artery Aneurysm
Švihlová, Helena , Sejkorová, Alena , Radovnický, Tomáš , Adámek, Daniel, Hron, J. , Dragomir‐Daescu, Dan , Málek, Josef , Sameš, Martin, Hejčl, Aleš , Dragomir-Daescu, Dan, Sejkorová, Alena , Hejčl, Aleš , Hron, Jaroslav , Švihlová, Helena

Mayo Clinic

Journal of Neurological Surgery Part A: Central European Neurosurgery | August 11, 2017 | Volume: 78 | Issue: 06 | Pages: 610-616

10.1055/s-0037-1604286 | PMID 28800663 Get It

AbstractComputational fluid dynamics (CFD) has been studied as a tool for the stratification of aneurysm rupture risk. We performed CFD analysis in a patient operated on for a ruptured anterior communicating artery aneurysm. The point of rupture was identified during surgery. The aneurysm and blood vessels were segmented from computed tomography angiography to prepare a model for simulations. We found that the streamlines showed a concentrated inflow jet directed straight at the rupture point, and high wall shear stress was found at the point of rupture in the aneurysm sac. Thus specific local hemodynamics may be indicative of the aneurysm rupture site.
Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations
Durham, Benjamin H. , Getta, Bartlomiej , Won, Helen , Scott, Sasinya N., Chung, Young Rock , Chung, Stephen S. , Hüllein, Jennifer , Walther, Tatjana, Wang, Lu , Oakes, Christopher C. , Tibes, Raoul , Haferlach, Torsten , Taylor, Barry S. , Tallman, Martin S. , Park, Jae H. , Bogenberger, James M. , Abdel-Wahab, Omar , Dietrich, Sascha , Taylor, Justin , Kim, Eun Hee , Lu, Sydney X. , Berger, Michael , Zenz, Thorsten , Abdel‐Wahab, Omar , Durham, Benjamin

Mayo Clinic

Blood | August 11, 2017 | Volume: 130 | Issue: 14 | Pages: 1644-1648

10.1182/blood-2017-01-765107 | PMID 28801450 Get It

Key Points KMT2C mutations occur in 15% and 25% of patients with cHCL and vHCL, respectively, along with CCND3 and U2AF1 mutations each in 13% of vHCLs. NF1, NF2, N/KRAS, and IRS1 alterations contribute to clinical resistance to vemurafenib treatment in patients with cHCL.
An update on hormone therapy in postmenopausal women: mini-review for the basic scientist
Miller, Virginia M. , Harman, S. Mitchell

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | August 11, 2017 | Volume: 313 | Issue: 5 | Pages: H1013-H1021

10.1152/ajpheart.00383.2017 | PMID 28801526 Get It

The worlds of observational, clinical, and basic science collided in 2002 with the publication of results of the Women’s Health Initiative (WHI), a large-scale, prospective, blinded, randomized-controlled trial designed to provide evidence regarding use of hormone treatment to prevent cardiovascular disease in menopausal women. The results of the WHI dramatically changed clinical practice, negatively impacted funding for hormone research, and left scientists to unravel the “why” of the results. Now over a decade and a half since the initial publication of the WHI results, basic and clinical scientists often do not interpret the results of the WHI with the precision needed to move the science forward. This review will 1) describe the historical background leading up to the WHI, 2) list the outcomes from the WHI, and put them in perspective with results of subsequent analysis of the WHI data and results from other prospective menopausal hormone treatment trials addressing cardiovascular effects of menopausal hormone use, and 3) articulate how the collective results are influencing current clinical care with the intent to provide guidance for designing and evaluating relevant new hormonal studies. Listen to this article's corresponding podcast at http://ajpheart.podbean.com/e/update-on-hormone-therapy-trials/ .
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer
Haricharan, Svasti , Punturi, Nindo , Singh, Purba , Holloway, Kimberly R. , Schmelz, Jacob , Schmidt, Cheryl, Lei, Jonathan T. , Li, Shunqiang , Huang, Shixia , Edwards, Dean P., Kavuri, Shyam M. , Bainbridge, Matthew N. , Cynthia, X. , Suman, Vera, Anurag, Meenakshi , Suman, Vera J. , Hunt, Kelly K. , Olson, John A. , Hoog, Jeremy , Ellis, Matthew J. , Lei, Jonathan T

Mayo Clinic

Cancer Discovery | August 11, 2017 | Volume: 7 | Issue: 10 | Pages: 1168-1183

10.1158/2159-8290.cd-16-1179 | PMID 28801307 Get It

Abstract Significant endocrine therapy–resistant tumor proliferation is present in ≥20% of estrogen receptor–positive (ER+) primary breast cancers and is associated with disease recurrence and death. Here, we uncover a link between intrinsic endocrine therapy resistance and dysregulation of the MutL mismatch repair (MMR) complex (MLH1/3, PMS1/2), and demonstrate a direct role for MutL complex loss in resistance to all classes of endocrine therapy. We find that MutL deficiency in ER+ breast cancer abrogates CHK2-mediated inhibition of CDK4, a prerequisite for endocrine therapy responsiveness. Consequently, CDK4/6 inhibitors (CDK4/6i) remain effective in MutL-defective ER+ breast cancer cells. These observations are supported by data from a clinical trial where a CDK4/6i was found to strongly inhibit aromatase inhibitor–resistant proliferation of MutL-defective tumors. These data suggest that diagnostic markers of MutL deficiency could be used to direct adjuvant CDK4/6i to a population of patients with breast cancer who exhibit marked resistance to the current standard of care. Significance: MutL deficiency in a subset of ER+ primary tumors explains why CDK4/6 inhibition is effective against some de novo endocrine therapy–resistant tumors. Therefore, markers of MutL dysregulation could guide CDK4/6 inhibitor use in the adjuvant setting, where the risk benefit ratio for untargeted therapeutic intervention is narrow. Cancer Discov; 7(10); 1168–83. ©2017 AACR. This article is highlighted in the In This Issue feature, p. 1047
Progressive Fibrosis: A Progesterone- and KLF11-Mediated Sexually Dimorphic Female Response
Shenoy, Chandra C. , Khan, Zaraq , Zheng, Ye , Jones, T.L., Khazaie, Khashayarsha , Daftary, Gaurang S., Jones, Tiffanny L

Mayo Clinic

Endocrinology | August 11, 2017 | Volume: 158 | Issue: 10 | Pages: 3605-3619

10.1210/en.2017-00171 | PMID 28938437 Get It